^
    Back
    Association details:
    Biomarker:ER negative + HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.

    Published date:
    05/19/2021
    Excerpt:
    ...ER+ HER2- MBC who received CDK4/6 inhibitor plus either letrozole or fulvestrant...HER2-low expression was associated with a significantly shorter PFS...ER+ HER2- MBC treated with CDK4/6 inhibitors, HER2-low expression was associated with an inferior PFS...
    Secondary therapy:
    letrozole; fulvestrant
    DOI:
    10.1200/JCO.2021.39.15_suppl.1052